MD1094Z - Method for diagnosis of gastroesophageal reflux disease - Google Patents

Method for diagnosis of gastroesophageal reflux disease

Info

Publication number
MD1094Z
MD1094Z MDS20160048A MDS20160048A MD1094Z MD 1094 Z MD1094 Z MD 1094Z MD S20160048 A MDS20160048 A MD S20160048A MD S20160048 A MDS20160048 A MD S20160048A MD 1094 Z MD1094 Z MD 1094Z
Authority
MD
Moldova
Prior art keywords
diagnosis
gastroesophageal reflux
reflux disease
symptoms
disease
Prior art date
Application number
MDS20160048A
Other languages
Romanian (ro)
Russian (ru)
Inventor
Влада-Татьяна ДУМБРАВА
Юлианна ЛУПАШКО
Анатолие ГРИБИНЮК
Инна ВЕНГЕР
Original Assignee
ОП ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ И ФАРМАЦЕВТИЧЕСКИЙ УНИВЕРСИТЕТ им. НИКОЛАЯ ТЕСТЕМИЦАНУ РЕСПУБЛИКИ МОЛДОВА
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОП ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ И ФАРМАЦЕВТИЧЕСКИЙ УНИВЕРСИТЕТ им. НИКОЛАЯ ТЕСТЕМИЦАНУ РЕСПУБЛИКИ МОЛДОВА filed Critical ОП ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ И ФАРМАЦЕВТИЧЕСКИЙ УНИВЕРСИТЕТ им. НИКОЛАЯ ТЕСТЕМИЦАНУ РЕСПУБЛИКИ МОЛДОВА
Priority to MDS20160048A priority Critical patent/MD1094Z/en
Publication of MD1094Y publication Critical patent/MD1094Y/en
Publication of MD1094Z publication Critical patent/MD1094Z/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to medicine, in particular to gastroenterology and may be used for diagnosis of gastroesophageal reflux disease.Summary of the invention consists in that it is carried out the clinical examination, and then is administered 20 mg of (RS)-2-([4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole, per os, and after 24 hours is repeatedly carried out the clinical examination with assessment of symptoms, such as retrosternal pain, regurgitations, namely their duration and expression, the factors that improve and/or deteriorate them, the impact of these symptoms on the quality of life, by assigning points for each symptom. In the case where the total score is up to 53, it is determined the absence of the disease, and when is 53 or more - it is set the diagnosis of gastroesophageal reflux disease.
MDS20160048A 2016-03-31 2016-03-31 Method for diagnosis of gastroesophageal reflux disease MD1094Z (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDS20160048A MD1094Z (en) 2016-03-31 2016-03-31 Method for diagnosis of gastroesophageal reflux disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDS20160048A MD1094Z (en) 2016-03-31 2016-03-31 Method for diagnosis of gastroesophageal reflux disease

Publications (2)

Publication Number Publication Date
MD1094Y MD1094Y (en) 2016-11-30
MD1094Z true MD1094Z (en) 2017-06-30

Family

ID=57424890

Family Applications (1)

Application Number Title Priority Date Filing Date
MDS20160048A MD1094Z (en) 2016-03-31 2016-03-31 Method for diagnosis of gastroesophageal reflux disease

Country Status (1)

Country Link
MD (1) MD1094Z (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2725603C1 (en) * 2020-03-30 2020-07-02 Федеральное государственное бюджетное образовательное учреждение высшего образования Северо-Западный государственный медицинский университет им. И.И. Мечникова Министерства здравоохранения Российской Федерации Method for non-invasive diagnosis of gastroesophageal reflux disease phenotypes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1304804A1 (en) * 1984-09-25 1987-04-23 Минский государственный медицинский институт Method of diagnosis of gastroesophageal reflux
SU1364347A1 (en) * 1985-12-10 1988-01-07 Латвийский Научно-Исследовательский Институт Экспериментальной И Клинической Медицины Method of diagnosis of gastroesophageal reflux
SU1380731A1 (en) * 1986-02-27 1988-03-15 Днепропетровский Научно-Исследовательский Институт Гастроэнтерологии Method of determining the degree of manifestation of gastroesophageal reflux by means of ph-probing of stomach
SU1421307A1 (en) * 1985-05-27 1988-09-07 Минский государственный медицинский институт Method of diagnosis of gastroesophageal reflux of children
MD202G2 (en) * 1993-05-05 1996-01-31 Государственный Университет Молд0 Method of active gamma-MnO2 preparing
MD2160G2 (en) * 2003-01-23 2003-11-30 СКОРПАН Анатолие Method of diagnosis of the reflux esophagitis gravity degree

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1304804A1 (en) * 1984-09-25 1987-04-23 Минский государственный медицинский институт Method of diagnosis of gastroesophageal reflux
SU1421307A1 (en) * 1985-05-27 1988-09-07 Минский государственный медицинский институт Method of diagnosis of gastroesophageal reflux of children
SU1364347A1 (en) * 1985-12-10 1988-01-07 Латвийский Научно-Исследовательский Институт Экспериментальной И Клинической Медицины Method of diagnosis of gastroesophageal reflux
SU1380731A1 (en) * 1986-02-27 1988-03-15 Днепропетровский Научно-Исследовательский Институт Гастроэнтерологии Method of determining the degree of manifestation of gastroesophageal reflux by means of ph-probing of stomach
MD202G2 (en) * 1993-05-05 1996-01-31 Государственный Университет Молд0 Method of active gamma-MnO2 preparing
MD2160G2 (en) * 2003-01-23 2003-11-30 СКОРПАН Анатолие Method of diagnosis of the reflux esophagitis gravity degree

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
American gastroenterological association. Medical Position Statement: Guidelines on the Use of Esophageal pH. Gastroenterology, 1996, vol.110, p.1981-1996 *
Jones R., Junghard O., Dent J. et al. Development of the GERDQ, a tool for diagnosis and management of gastro-esofageal reflux disease in primary care. Aliment. Pharmacol. Ter., 2009, 30, p. 1030-1038 *
Katz P.O., Gerson L.B., Vela M.F. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am. J. Gastroenterol., 2013, 108, p. 308-328 *
Position Statement: Guidelines on the Use of Esophageal pH. Gastroenterology, 1996, vol.110, p.1981-1996. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2725603C1 (en) * 2020-03-30 2020-07-02 Федеральное государственное бюджетное образовательное учреждение высшего образования Северо-Западный государственный медицинский университет им. И.И. Мечникова Министерства здравоохранения Российской Федерации Method for non-invasive diagnosis of gastroesophageal reflux disease phenotypes

Also Published As

Publication number Publication date
MD1094Y (en) 2016-11-30

Similar Documents

Publication Publication Date Title
RU2017114346A (en) ANTAGONISTS INTEGRINE ανβ6
CN106659757A8 (en) The super agonist of interleukin-22, partial agonist and antagonist
UA117103C2 (en) Glucagon analogues
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
MX2018013476A (en) Compositions for treating acid-base disorders.
EA201890891A1 (en) BIOMARKERS ASSOCIATED WITH INTERLEYKIN-33 DISEASES, AND THEIR APPLICATION
EA201790563A1 (en) APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY
TW201613932A (en) Organic compounds
EA201791021A1 (en) 1- [2- (AMINOMETHYL) BENZYL] -2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO [3,2-d] PYRIMIDIN-4-ONE AS INHIBITORS MYELOPEROXIDASE
EA201401353A1 (en) BIOMARKERS TO DETERMINE AN EFFECTIVE RESPONSE RESPONSE TO THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
MX2018000883A (en) Crystalline forms of bilastine and preparation methods thereof.
WO2011137322A3 (en) Methods and compositions for treating celiac disease
MD1094Y (en) Method for diagnosis of gastroesophageal reflux disease
WO2014169011A3 (en) Methods for treating immune diseases
WO2015120436A3 (en) Stat3 phosphorylation during graft-versus-host disease
WO2018204377A3 (en) TUMOR VS. MATCHED NORMAL cfRNA
Haines et al. C44 critical illness predictors and outcomes: longer term outcomes following critical care: preliminary results of the Australian experience
EA201491870A1 (en) METHOD OF TREATING HYPERURICEMIA IN PATIENTS WITH GONATHRITIS THROUGH HALOPHENATE OR HALOPHENIC ACID AND ANTI-INFLAMMATORY AGENT
Paly et al. The prevalence of gastroesophageal reflux disease in patients with pathology digestive system, the triggers and effective blocker of Н+/K+-ATPase (according to the survey of outpatients)
Brownschidle Melaena: case report
Blanco et al. C52 CLINICAL EVALUATION AND BIOMARKERS OF PULMONARY HYPERTENSION I: Quality Of Life In Pulmonary Hypertension: Impact Of Proper Medical Treatment
Yusupaliieva The quality of life in patients with chronic obstructive pulmonary disease with comorbid arterial hypertension
Elahee et al. C70 CALL MY NAME: CASE REPORTS IN PULMONARY VASCULAR DISEASE: Rivaroxaban Treatment Failure: A Case Report
Hatemi Pneumonia, respiratory failure and sepsis: case report
XIN et al. Synergistic effect of family hypertension history and hyperuricemia on incidence of hypertension

Legal Events

Date Code Title Description
FG9Y Short term patent issued
KA4Y Short-term patent lapsed due to non-payment of fees (with right of restoration)